Philikos aims to change the treatment landscape of scleroderma and other severe immune disorders by using its innovative T-Guard compound to rapidly and safely reset the patient’s immune system thereby restoring normal immune function and providing patients with a healthier long-term outlook.
Our Solution: T-Guard
Our solution is T-Guard, a combination of two toxin-conjugated antibodies that rebalances the immune system by transient depletion of activated autoreactive T cells and NK cells, which are key immune cells in the diseae process of systemic sclerosis. T-Guard has the potential to rebalance the immune system by transient depletion of T cells and NK cells, providing a therapeutic approach with potentially better benefit/risk profile than a hematopoietic stem cell transplantation (HSCT).
Participating site for PoP study
Radboud university medical center (Radboudumc) is a leading Dutch academic centre for medical science, education and health care. The Radboudumc is located in the city of Nijmegen, in the eastern-central part of the Netherlands, as the teaching hospital affiliated with the Radboud University Nijmegen. The Radboudumc Rheumatology Department has performed research on systemic sclerosis since 1988. Being a national referral center, the Rheumatology center treats over one third of all Dutch SSc patients.